GEMCOVAC®-19
Gennova’s mRNA vaccine, GEMCOVAC®-19, which is stable at 2-8°C,
has received the Emergency Use Authorization (EUA)
Gennova’s mRNA vaccine, GEMCOVAC®-19, which is stable at 2-8°C,
has received the Emergency Use Authorization (EUA)
Developed to address the problems in the earlier approved mRNA vaccines.
The mRNA development platform has the potential to develop rapidly.
GEMCOVAC® mRNA vaccine is stable at 2–8 °C and can be considered superior in terms of deployability in India and other developing nations (especially LMICs) compared to other approved mRNA vaccines.
CIN – U24231PN2001PLC016253
T-184, MIDC, Bhosari, Pune – 411 026,
Maharashtra, India.
BTS – 2 Building, Chrysalis Enclave, Block – 2, Plot -2,
TCG International Biotech Park,
Phase II, MIDC, Hinjawadi, Pune – 411 057,
Maharashtra – India
Block -1, Plot P1 & P2, ITBT Park, Phase II, MIDC,
Hinjawadi, Pune – 411 057, Maharashtra, India.
Copyright © 2023 Gennova Biopharmaceuticals Limited - All Rights Reserved.